• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Pristimerin-induced uveal melanoma cell death via inhibiting PI3K/Akt/FoxO3a signalling pathway.
Abstract Uveal melanoma (UM) is a highly invasive intraocular malignancy with high mortality. Presently, there is no FDA-approved standard for the treatment of metastatic UM. Pristimerin is a natural quinine methide triterpenoid compound with anti-angiogenic, anti-cancer and anti-inflammatory activities. However, Pristimerin potential cytotoxic effect on UM was poorly investigated. In the present study, we found the migration and invasion of UM-1 cells were inhibited by Pristimerin which also caused a rapid increase of ROS, decreased mitochondrial membrane potential, induced the accumulation of cells in G0/G1 phas...
Source: J Cell Mol Med - April 28, 2020 Category: Molecular Biology Authors: Yan F, Liao R, Silva M, Li S, Jiang Y, Peng T, Lazarovici P, Zheng W Tags: J Cell Mol Med Source Type: research

Sclerostin Suppression Facilitates Uveal Melanoma Progression Through Activating Wnt/ β-Catenin Signaling Via Binding to Membrane Receptors LRP5/LRP6
ConclusionSOST silencing may facilitate the malignant progression of UM cells through activating Wnt/β-catenin signaling. Mechanistically, SOST may exert this function by interacting with LRP5/LRP6 membrane receptors.
Source: Frontiers in Oncology - June 17, 2022 Category: Cancer & Oncology Source Type: research

Inhibition of CD146 lessens uveal melanoma progression through reducing angiogenesis and vasculogenic mimicry
ConclusionsCD146 is a novel mediator of both angiogenesis and vasculogenic mimicry in uveal melanoma. Its antibody AA98 has the potency to be developed as a new antibody drug for treating uveal melanoma. Our results warrant further assessment of CD146 as a potential target to improve therapeutic management of uveal melanoma in a clinical setting.
Source: Cellular Oncology - June 18, 2022 Category: Cancer & Oncology Source Type: research

Cancers, Vol. 14, Pages 3122: Cordycepin (3 & prime;-Deoxyadenosine) Suppresses Heat Shock Protein 90 Function and Targets Tumor Growth in an Adenosine Deaminase-Dependent Manner
Cancers, Vol. 14, Pages 3122: Cordycepin (3′-Deoxyadenosine) Suppresses Heat Shock Protein 90 Function and Targets Tumor Growth in an Adenosine Deaminase-Dependent Manner Cancers doi: 10.3390/cancers14133122 Authors: Su-Chan Lee Lujain Alaali HyukJean Kwon Mohammed Rigi Charles G. Eberhart Alterations in metabolism and energy production are increasingly being recognized as important drivers of neoplasia, raising the possibility that metabolic analogs could disrupt oncogenic pathways. 3′-deoxyadenosine, also known as cordycepin, is an adenosine analog that inhibits the growth of sever...
Source: Cancers - June 25, 2022 Category: Cancer & Oncology Authors: Su-Chan Lee Lujain Alaali HyukJean Kwon Mohammed Rigi Charles G. Eberhart Tags: Article Source Type: research

Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior
Oncotarget. 2023 Mar 21;14:219-235. doi: 10.18632/oncotarget.28388.ABSTRACTGlypicans (GPC1-6) are associated with tumorigenic processes and their involvement in neoplastic behavior has been discussed in different cancer types. Here, a cancer-wide GPC expression study, using clinical cancer patient data in The Cancer Genome Atlas, reveals net upregulation of GPC1 and GPC2 in primary solid tumors, whereas GPC3, GPC5 and GPC6 display lowered expression pattern compared to normal tissues. Focusing on GPC1, survival analyses of the clinical cancer patient data reveal statistically significant correlation between high expression...
Source: Oncotarget - March 21, 2023 Category: Cancer & Oncology Authors: Fang Cheng Victor Ch érouvrier Hansson Grigorios Georgolopoulos Katrin Mani Source Type: research

MYC induces immunotherapy and interferon- γ resistance through downregulation of JAK2
Cancer Immunol Res. 2023 Apr 19:CIR-22-0184. doi: 10.1158/2326-6066.CIR-22-0184. Online ahead of print.ABSTRACTImmunotherapy has revolutionized the treatment of advanced melanoma. Because the pathways mediating resistance to immunotherapy are largely unknown, we conducted transcriptome profiling of pre-immunotherapy tumor biopsies from melanoma patients that received PD-1 blockade or adoptive cell therapy with tumor-infiltrating lymphocytes. We identified two melanoma-intrinsic, mutually exclusive gene programs, which were controlled by interferon-γ (IFNγ) and MYC, and the association with immunotherapy outcome. MYC-over...
Source: Cell Research - April 19, 2023 Category: Cytology Authors: Ettai Markovits Ortal Harush Erez N Baruch Eldad D Shulman Assaf Debby Orit Itzhaki Liat Anafi Artem Danilevsky Noam Shomron Guy Ben-Betzalel Nethanel Asher Ronnie Shapira-Frommer Jacob Schachter Iris Barshack Tamar Geiger Ran Elkon Michal J Besser Gal Ma Source Type: research

Pages: 1  2